The rate of CD49d expression on de novo Acute Myeloid Leukemia Patients

Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell disorder, characterized by arrested differentiation, inappropriate proliferation and survival of immature myeloid progenitors.The AML has the lowest survival rate of all leukemias. So, assessment of the prognostic factors in AML is very important. Recently, CD49d expression was described to have a prognostic impact in AML.The present study planned to assess CD49d expression in patients with AML, and to evaluate its association with the different demographic, clinical and laboratory data, as well as its relation to disease outcome.The current study was carried out on 30 newly diagnosed AML patients. All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: complete blood picture, bone marrow aspiration with examination of Leishman-stained peripheral blood and bone marrow smears, immunophenotyping, cytogenetic study and detection of the level of CD49d expression by flowcytometry.Using the receiver operating characteristic (ROC) curve, cut-off values for CD49d were evaluated and identified in order to allow the most significant separation and differentiation between AML cases with remission or relapse/death. The cut-off value for CD49d% was 74.92% to diagnose AML cases..